nodes	percent_of_prediction	percent_of_DWPC	metapath
Rizatriptan—Hoarseness—Varenicline—nicotine dependence	0.0266	0.0402	CcSEcCtD
Rizatriptan—Parosmia—Varenicline—nicotine dependence	0.018	0.0273	CcSEcCtD
Rizatriptan—Menstrual disorder—Varenicline—nicotine dependence	0.0172	0.0259	CcSEcCtD
Rizatriptan—Rhinorrhoea—Varenicline—nicotine dependence	0.0144	0.0218	CcSEcCtD
Rizatriptan—Dysphonia—Varenicline—nicotine dependence	0.0142	0.0215	CcSEcCtD
Rizatriptan—Eye irritation—Varenicline—nicotine dependence	0.0137	0.0207	CcSEcCtD
Rizatriptan—Disturbance in attention—Varenicline—nicotine dependence	0.0135	0.0204	CcSEcCtD
Rizatriptan—Lacrimation increased—Varenicline—nicotine dependence	0.0127	0.0192	CcSEcCtD
Rizatriptan—Dysarthria—Varenicline—nicotine dependence	0.0124	0.0187	CcSEcCtD
Rizatriptan—Coordination abnormal—Varenicline—nicotine dependence	0.0119	0.018	CcSEcCtD
Rizatriptan—Musculoskeletal pain—Varenicline—nicotine dependence	0.0118	0.0179	CcSEcCtD
Rizatriptan—Blood pressure increased—Varenicline—nicotine dependence	0.0117	0.0177	CcSEcCtD
Rizatriptan—Eructation—Varenicline—nicotine dependence	0.0115	0.0174	CcSEcCtD
Rizatriptan—Photophobia—Varenicline—nicotine dependence	0.011	0.0166	CcSEcCtD
Rizatriptan—Dry eye—Varenicline—nicotine dependence	0.0108	0.0163	CcSEcCtD
Rizatriptan—Urine output increased—Varenicline—nicotine dependence	0.0106	0.016	CcSEcCtD
Rizatriptan—HTR1F—Monoamine GPCRs—DRD2—nicotine dependence	0.0104	0.04	CbGpPWpGaD
Rizatriptan—Sumatriptan—DRD2—nicotine dependence	0.0103	1	CrCbGaD
Rizatriptan—Euphoric mood—Varenicline—nicotine dependence	0.0101	0.0152	CcSEcCtD
Rizatriptan—Polyuria—Varenicline—nicotine dependence	0.00967	0.0146	CcSEcCtD
Rizatriptan—Disorientation—Varenicline—nicotine dependence	0.00949	0.0143	CcSEcCtD
Rizatriptan—Deafness—Varenicline—nicotine dependence	0.00949	0.0143	CcSEcCtD
Rizatriptan—Eye pain—Varenicline—nicotine dependence	0.00941	0.0142	CcSEcCtD
Rizatriptan—Hot flush—Varenicline—nicotine dependence	0.00908	0.0137	CcSEcCtD
Rizatriptan—Increased appetite—Varenicline—nicotine dependence	0.00904	0.0137	CcSEcCtD
Rizatriptan—Menopausal symptoms—Varenicline—nicotine dependence	0.009	0.0136	CcSEcCtD
Rizatriptan—Thirst—Varenicline—nicotine dependence	0.00892	0.0135	CcSEcCtD
Rizatriptan—HTR1F—brain—nicotine dependence	0.0089	0.131	CbGeAlD
Rizatriptan—HTR1F—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00874	0.0336	CbGpPWpGaD
Rizatriptan—Cerebrovascular accident—Varenicline—nicotine dependence	0.00867	0.0131	CcSEcCtD
Rizatriptan—Osteoarthritis—Varenicline—nicotine dependence	0.00849	0.0128	CcSEcCtD
Rizatriptan—Irritability—Varenicline—nicotine dependence	0.0081	0.0122	CcSEcCtD
Rizatriptan—Cramp muscle—Varenicline—nicotine dependence	0.00765	0.0116	CcSEcCtD
Rizatriptan—Nasopharyngitis—Varenicline—nicotine dependence	0.00759	0.0115	CcSEcCtD
Rizatriptan—Gastritis—Varenicline—nicotine dependence	0.00751	0.0114	CcSEcCtD
Rizatriptan—HTR1B—cardiovascular system—nicotine dependence	0.00743	0.109	CbGeAlD
Rizatriptan—Abdominal distension—Varenicline—nicotine dependence	0.00739	0.0112	CcSEcCtD
Rizatriptan—Dysphagia—Varenicline—nicotine dependence	0.00734	0.0111	CcSEcCtD
Rizatriptan—HTR1D—cardiovascular system—nicotine dependence	0.0072	0.105	CbGeAlD
Rizatriptan—Angina pectoris—Varenicline—nicotine dependence	0.00715	0.0108	CcSEcCtD
Rizatriptan—HTR1F—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00709	0.0273	CbGpPWpGaD
Rizatriptan—Abdominal discomfort—Varenicline—nicotine dependence	0.00704	0.0106	CcSEcCtD
Rizatriptan—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.00679	0.0261	CbGpPWpGaD
Rizatriptan—Pollakiuria—Varenicline—nicotine dependence	0.00678	0.0102	CcSEcCtD
Rizatriptan—Photosensitivity reaction—Varenicline—nicotine dependence	0.0067	0.0101	CcSEcCtD
Rizatriptan—HTR1D—Monoamine GPCRs—DRD2—nicotine dependence	0.00665	0.0256	CbGpPWpGaD
Rizatriptan—HTR1B—Monoamine GPCRs—DRD2—nicotine dependence	0.00651	0.025	CbGpPWpGaD
Rizatriptan—Acute coronary syndrome—Varenicline—nicotine dependence	0.00645	0.00975	CcSEcCtD
Rizatriptan—Myocardial infarction—Varenicline—nicotine dependence	0.00641	0.00969	CcSEcCtD
Rizatriptan—MAOA—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0062	0.0238	CbGpPWpGaD
Rizatriptan—Epistaxis—Varenicline—nicotine dependence	0.00617	0.00933	CcSEcCtD
Rizatriptan—HTR1A—cardiovascular system—nicotine dependence	0.006	0.0879	CbGeAlD
Rizatriptan—Bradycardia—Varenicline—nicotine dependence	0.00598	0.00904	CcSEcCtD
Rizatriptan—Hallucination—Varenicline—nicotine dependence	0.00584	0.00883	CcSEcCtD
Rizatriptan—Hypoaesthesia—Varenicline—nicotine dependence	0.00584	0.00883	CcSEcCtD
Rizatriptan—HTR1B—midbrain—nicotine dependence	0.0058	0.0851	CbGeAlD
Rizatriptan—HTR1D—midbrain—nicotine dependence	0.00562	0.0824	CbGeAlD
Rizatriptan—HTR1D—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00559	0.0215	CbGpPWpGaD
Rizatriptan—MAOA—cardiovascular system—nicotine dependence	0.00548	0.0803	CbGeAlD
Rizatriptan—Tinnitus—Varenicline—nicotine dependence	0.00548	0.00828	CcSEcCtD
Rizatriptan—HTR1B—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00547	0.0211	CbGpPWpGaD
Rizatriptan—Angiopathy—Varenicline—nicotine dependence	0.00533	0.00805	CcSEcCtD
Rizatriptan—Chills—Varenicline—nicotine dependence	0.00527	0.00797	CcSEcCtD
Rizatriptan—Arrhythmia—Varenicline—nicotine dependence	0.00525	0.00793	CcSEcCtD
Rizatriptan—Mental disorder—Varenicline—nicotine dependence	0.00515	0.00778	CcSEcCtD
Rizatriptan—Erythema—Varenicline—nicotine dependence	0.00511	0.00773	CcSEcCtD
Rizatriptan—Flatulence—Varenicline—nicotine dependence	0.00504	0.00762	CcSEcCtD
Rizatriptan—Dysgeusia—Varenicline—nicotine dependence	0.00501	0.00757	CcSEcCtD
Rizatriptan—HTR1A—Monoamine GPCRs—DRD2—nicotine dependence	0.00496	0.0191	CbGpPWpGaD
Rizatriptan—Muscle spasms—Varenicline—nicotine dependence	0.00492	0.00743	CcSEcCtD
Rizatriptan—Vision blurred—Varenicline—nicotine dependence	0.00482	0.00728	CcSEcCtD
Rizatriptan—Tremor—Varenicline—nicotine dependence	0.00479	0.00724	CcSEcCtD
Rizatriptan—Agitation—Varenicline—nicotine dependence	0.0047	0.0071	CcSEcCtD
Rizatriptan—HTR1A—midbrain—nicotine dependence	0.00468	0.0687	CbGeAlD
Rizatriptan—Angioedema—Varenicline—nicotine dependence	0.00467	0.00706	CcSEcCtD
Rizatriptan—Vertigo—Varenicline—nicotine dependence	0.00459	0.00694	CcSEcCtD
Rizatriptan—Syncope—Varenicline—nicotine dependence	0.00459	0.00693	CcSEcCtD
Rizatriptan—HTR1D—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00453	0.0175	CbGpPWpGaD
Rizatriptan—Palpitations—Varenicline—nicotine dependence	0.00452	0.00683	CcSEcCtD
Rizatriptan—Loss of consciousness—Varenicline—nicotine dependence	0.00449	0.00679	CcSEcCtD
Rizatriptan—Cough—Varenicline—nicotine dependence	0.00446	0.00674	CcSEcCtD
Rizatriptan—HTR1B—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00444	0.0171	CbGpPWpGaD
Rizatriptan—Convulsion—Varenicline—nicotine dependence	0.00443	0.0067	CcSEcCtD
Rizatriptan—Hypertension—Varenicline—nicotine dependence	0.00441	0.00667	CcSEcCtD
Rizatriptan—Myalgia—Varenicline—nicotine dependence	0.00435	0.00658	CcSEcCtD
Rizatriptan—Chest pain—Varenicline—nicotine dependence	0.00435	0.00658	CcSEcCtD
Rizatriptan—Arthralgia—Varenicline—nicotine dependence	0.00435	0.00658	CcSEcCtD
Rizatriptan—Anxiety—Varenicline—nicotine dependence	0.00434	0.00656	CcSEcCtD
Rizatriptan—Discomfort—Varenicline—nicotine dependence	0.0043	0.0065	CcSEcCtD
Rizatriptan—HTR1F—GPCR ligand binding—TAS2R16—nicotine dependence	0.00429	0.0165	CbGpPWpGaD
Rizatriptan—MAOA—midbrain—nicotine dependence	0.00428	0.0627	CbGeAlD
Rizatriptan—Dry mouth—Varenicline—nicotine dependence	0.00426	0.00643	CcSEcCtD
Rizatriptan—MAOA—Transmission across Chemical Synapses—CHRNB3—nicotine dependence	0.00426	0.0164	CbGpPWpGaD
Rizatriptan—Oedema—Varenicline—nicotine dependence	0.00417	0.00631	CcSEcCtD
Rizatriptan—HTR1A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00417	0.016	CbGpPWpGaD
Rizatriptan—Shock—Varenicline—nicotine dependence	0.00411	0.00621	CcSEcCtD
Rizatriptan—Nervous system disorder—Varenicline—nicotine dependence	0.00409	0.00619	CcSEcCtD
Rizatriptan—Tachycardia—Varenicline—nicotine dependence	0.00407	0.00616	CcSEcCtD
Rizatriptan—MAOA—Transmission across Chemical Synapses—CHRNA6—nicotine dependence	0.00404	0.0155	CbGpPWpGaD
Rizatriptan—Hyperhidrosis—Varenicline—nicotine dependence	0.00403	0.0061	CcSEcCtD
Rizatriptan—Anorexia—Varenicline—nicotine dependence	0.00398	0.00601	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.0038	0.00575	CcSEcCtD
Rizatriptan—Insomnia—Varenicline—nicotine dependence	0.00377	0.0057	CcSEcCtD
Rizatriptan—Dyspnoea—Varenicline—nicotine dependence	0.00372	0.00562	CcSEcCtD
Rizatriptan—Somnolence—Varenicline—nicotine dependence	0.00371	0.00561	CcSEcCtD
Rizatriptan—Dyspepsia—Varenicline—nicotine dependence	0.00367	0.00555	CcSEcCtD
Rizatriptan—HTR1B—brain—nicotine dependence	0.00365	0.0535	CbGeAlD
Rizatriptan—Decreased appetite—Varenicline—nicotine dependence	0.00363	0.00548	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Varenicline—nicotine dependence	0.0036	0.00545	CcSEcCtD
Rizatriptan—Fatigue—Varenicline—nicotine dependence	0.0036	0.00544	CcSEcCtD
Rizatriptan—Pain—Varenicline—nicotine dependence	0.00357	0.00539	CcSEcCtD
Rizatriptan—Constipation—Varenicline—nicotine dependence	0.00357	0.00539	CcSEcCtD
Rizatriptan—HTR1D—brain—nicotine dependence	0.00353	0.0518	CbGeAlD
Rizatriptan—Feeling abnormal—Varenicline—nicotine dependence	0.00344	0.0052	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Varenicline—nicotine dependence	0.00341	0.00516	CcSEcCtD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00341	0.0131	CbGpPWpGaD
Rizatriptan—HTR1A—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00338	0.013	CbGpPWpGaD
Rizatriptan—Urticaria—Varenicline—nicotine dependence	0.00332	0.00501	CcSEcCtD
Rizatriptan—Abdominal pain—Varenicline—nicotine dependence	0.0033	0.00499	CcSEcCtD
Rizatriptan—Body temperature increased—Varenicline—nicotine dependence	0.0033	0.00499	CcSEcCtD
Rizatriptan—MAOA—Biological oxidations—CYP2A7—nicotine dependence	0.00329	0.0127	CbGpPWpGaD
Rizatriptan—MAOA—Neuronal System—CHRNB3—nicotine dependence	0.00326	0.0126	CbGpPWpGaD
Rizatriptan—MAOA—Neuronal System—CHRNA6—nicotine dependence	0.00309	0.0119	CbGpPWpGaD
Rizatriptan—Hypersensitivity—Varenicline—nicotine dependence	0.00307	0.00465	CcSEcCtD
Rizatriptan—Asthenia—Varenicline—nicotine dependence	0.00299	0.00453	CcSEcCtD
Rizatriptan—HTR1F—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00299	0.0115	CbGpPWpGaD
Rizatriptan—Pruritus—Varenicline—nicotine dependence	0.00295	0.00446	CcSEcCtD
Rizatriptan—HTR1A—brain—nicotine dependence	0.00294	0.0431	CbGeAlD
Rizatriptan—MAOA—Transmission across Chemical Synapses—GABRA4—nicotine dependence	0.00292	0.0112	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.0029	0.0112	CbGpPWpGaD
Rizatriptan—Diarrhoea—Varenicline—nicotine dependence	0.00286	0.00432	CcSEcCtD
Rizatriptan—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00282	0.0109	CbGpPWpGaD
Rizatriptan—MAOA—Transmission across Chemical Synapses—CHRNB4—nicotine dependence	0.0028	0.0108	CbGpPWpGaD
Rizatriptan—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00278	0.0107	CbGpPWpGaD
Rizatriptan—HTR1F—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00277	0.0107	CbGpPWpGaD
Rizatriptan—Dizziness—Varenicline—nicotine dependence	0.00276	0.00417	CcSEcCtD
Rizatriptan—HTR1D—GPCR ligand binding—TAS2R16—nicotine dependence	0.00275	0.0106	CbGpPWpGaD
Rizatriptan—MAOA—brain—nicotine dependence	0.00269	0.0394	CbGeAlD
Rizatriptan—HTR1B—GPCR ligand binding—TAS2R16—nicotine dependence	0.00269	0.0103	CbGpPWpGaD
Rizatriptan—Vomiting—Varenicline—nicotine dependence	0.00265	0.00401	CcSEcCtD
Rizatriptan—Rash—Varenicline—nicotine dependence	0.00263	0.00398	CcSEcCtD
Rizatriptan—Dermatitis—Varenicline—nicotine dependence	0.00263	0.00397	CcSEcCtD
Rizatriptan—Headache—Varenicline—nicotine dependence	0.00261	0.00395	CcSEcCtD
Rizatriptan—MAOA—Transmission across Chemical Synapses—CHRNA5—nicotine dependence	0.0026	0.01	CbGpPWpGaD
Rizatriptan—Nausea—Varenicline—nicotine dependence	0.00248	0.00375	CcSEcCtD
Rizatriptan—HTR1F—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00243	0.00934	CbGpPWpGaD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00238	0.00915	CbGpPWpGaD
Rizatriptan—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00229	0.0088	CbGpPWpGaD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00228	0.00876	CbGpPWpGaD
Rizatriptan—MAOA—Neuronal System—GABRA4—nicotine dependence	0.00224	0.0086	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—TAS2R16—nicotine dependence	0.0022	0.00848	CbGpPWpGaD
Rizatriptan—HTR1F—G alpha (i) signalling events—DRD2—nicotine dependence	0.00216	0.00832	CbGpPWpGaD
Rizatriptan—MAOA—Neuronal System—CHRNB4—nicotine dependence	0.00214	0.00825	CbGpPWpGaD
Rizatriptan—MAOA—Transmission across Chemical Synapses—CHRNA3—nicotine dependence	0.00212	0.00816	CbGpPWpGaD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00207	0.00796	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—TAS2R16—nicotine dependence	0.00205	0.00788	CbGpPWpGaD
Rizatriptan—HTR1F—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00201	0.00772	CbGpPWpGaD
Rizatriptan—MAOA—Neuronal System—CHRNA5—nicotine dependence	0.00199	0.00767	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00194	0.00745	CbGpPWpGaD
Rizatriptan—HTR1D—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00191	0.00736	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—FGD1—nicotine dependence	0.0019	0.00733	CbGpPWpGaD
Rizatriptan—HTR1B—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00187	0.0072	CbGpPWpGaD
Rizatriptan—MAOA—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.00187	0.00718	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—OPRM1—nicotine dependence	0.00181	0.00697	CbGpPWpGaD
Rizatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00177	0.00683	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00176	0.00676	CbGpPWpGaD
Rizatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00174	0.00669	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—FGD1—nicotine dependence	0.00173	0.00666	CbGpPWpGaD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00172	0.00661	CbGpPWpGaD
Rizatriptan—MAOA—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.00169	0.00652	CbGpPWpGaD
Rizatriptan—MAOA—Neuronal System—CHRNA3—nicotine dependence	0.00162	0.00625	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00155	0.00597	CbGpPWpGaD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00152	0.00585	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00152	0.00585	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00149	0.00573	CbGpPWpGaD
Rizatriptan—MAOA—Neuronal System—CHRNB2—nicotine dependence	0.00143	0.0055	CbGpPWpGaD
Rizatriptan—HTR1A—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00143	0.00549	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—TAS2R16—nicotine dependence	0.00141	0.00542	CbGpPWpGaD
Rizatriptan—HTR1D—G alpha (i) signalling events—DRD2—nicotine dependence	0.00138	0.00532	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—TAS2R16—nicotine dependence	0.00138	0.00531	CbGpPWpGaD
Rizatriptan—HTR1B—G alpha (i) signalling events—DRD2—nicotine dependence	0.00135	0.00521	CbGpPWpGaD
Rizatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00132	0.00509	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—DRD2—nicotine dependence	0.00131	0.00504	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—TAS2R16—nicotine dependence	0.0013	0.00501	CbGpPWpGaD
Rizatriptan—MAOA—Neuronal System—CHRNA4—nicotine dependence	0.0013	0.005	CbGpPWpGaD
Rizatriptan—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00129	0.00496	CbGpPWpGaD
Rizatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00128	0.00494	CbGpPWpGaD
Rizatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00126	0.00483	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—FGD1—nicotine dependence	0.00122	0.00469	CbGpPWpGaD
Rizatriptan—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.00121	0.00467	CbGpPWpGaD
Rizatriptan—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.0012	0.00461	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—FGD1—nicotine dependence	0.00119	0.00459	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—OPRM1—nicotine dependence	0.00116	0.00446	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00116	0.00445	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00113	0.00436	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—OPRM1—nicotine dependence	0.00113	0.00436	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—FGD1—nicotine dependence	0.00111	0.00426	CbGpPWpGaD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.0011	0.00423	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—FGD1—nicotine dependence	0.00108	0.00417	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00108	0.00414	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—TAS2R16—nicotine dependence	0.00105	0.00405	CbGpPWpGaD
Rizatriptan—HTR1A—G alpha (i) signalling events—DRD2—nicotine dependence	0.00103	0.00397	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—OPRM1—nicotine dependence	0.00102	0.00394	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—FGD1—nicotine dependence	0.00102	0.00393	CbGpPWpGaD
Rizatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000957	0.00368	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—OPRM1—nicotine dependence	0.000929	0.00358	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—FGD1—nicotine dependence	0.000908	0.0035	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—AKR1B10—nicotine dependence	0.000902	0.00347	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—OPRM1—nicotine dependence	0.000863	0.00332	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—DRD2—nicotine dependence	0.000837	0.00322	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—TAS2R16—nicotine dependence	0.000832	0.0032	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—FGD1—nicotine dependence	0.000825	0.00317	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00082	0.00316	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—DRD2—nicotine dependence	0.000819	0.00315	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—TAS2R16—nicotine dependence	0.000815	0.00314	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—DRD2—nicotine dependence	0.00074	0.00285	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—DRD2—nicotine dependence	0.000672	0.00258	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—OPRM1—nicotine dependence	0.000654	0.00252	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—FGD1—nicotine dependence	0.000653	0.00251	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—OPRM1—nicotine dependence	0.00064	0.00247	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—FGD1—nicotine dependence	0.00064	0.00246	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—WASF2—nicotine dependence	0.000636	0.00245	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—DRD2—nicotine dependence	0.000624	0.0024	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—TAS2R16—nicotine dependence	0.000621	0.00239	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—WASF1—nicotine dependence	0.000609	0.00235	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—OPRM1—nicotine dependence	0.000594	0.00229	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—OPRM1—nicotine dependence	0.000582	0.00224	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—AKR1B10—nicotine dependence	0.000577	0.00222	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—AKR1B10—nicotine dependence	0.000565	0.00217	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—CYP2A7—nicotine dependence	0.000563	0.00217	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—OPRM1—nicotine dependence	0.000549	0.00211	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—OPRM1—nicotine dependence	0.000488	0.00188	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—FGD1—nicotine dependence	0.000487	0.00188	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—DRD2—nicotine dependence	0.000473	0.00182	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—DRD2—nicotine dependence	0.000463	0.00178	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—OPRM1—nicotine dependence	0.000443	0.00171	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—AKR1B10—nicotine dependence	0.00043	0.00166	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—DRD2—nicotine dependence	0.000429	0.00165	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—DRD2—nicotine dependence	0.000421	0.00162	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—WASF2—nicotine dependence	0.000406	0.00156	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—WASF2—nicotine dependence	0.000398	0.00153	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—DRD2—nicotine dependence	0.000397	0.00153	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—WASF1—nicotine dependence	0.00039	0.0015	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—WASF1—nicotine dependence	0.000382	0.00147	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—DRD2—nicotine dependence	0.000353	0.00136	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—OPRM1—nicotine dependence	0.000351	0.00135	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—OPRM1—nicotine dependence	0.000344	0.00132	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—DRD2—nicotine dependence	0.00032	0.00123	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—WASF2—nicotine dependence	0.000303	0.00117	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—WASF1—nicotine dependence	0.000291	0.00112	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—OPRM1—nicotine dependence	0.000262	0.00101	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—DRD2—nicotine dependence	0.000254	0.000976	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—DRD2—nicotine dependence	0.000248	0.000956	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CYP2A7—nicotine dependence	0.000208	0.000799	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—DRD2—nicotine dependence	0.000189	0.000728	CbGpPWpGaD
